SoftMedx Healthcare Limited
2951.HK
Hong Kong Stock Exchange5.80
HKD
+0.06
- -
ISIN
HK0001311718
Return %
Stock
S&P500
1Y
-70.80
19.99
3Y
-70.80
68.07
5Y
-70.80
72.03
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Full Time Employees
- 20
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- China Hong Kong Tower Hong Kong Hong Kong
- IPO Date
- May 19, 2026
- Website
- 648.com.hk
- Similar Companies
- Business
- SoftMedx Healthcare Limited is a diversified healthcare group focused on medical services, healthcare-related products, and asset management; the company operates through multiple segments including medical and well-being services, health management, and asset management, and engages in the manufacturing and sale of pharmaceutical and health-related products, medical laboratory testing, health check and obstetric/gynaecological services, as well as operation of optical products and eye-care retail outlets; it also maintains investments in financial and fixed assets, distressed assets, and provides loan financing. The company is publicly listed on The Stock Exchange of Hong Kong Limited under ticker 2951.HK and is headquartered in Hong Kong with operations historically centered in Greater China, including Hong Kong and the mainland, while maintaining a broader international outlook through its asset management activities. SoftMedx was founded in 2001 and maintains strategic anchors in healthcare services, clinical diagnostics, eye-care retail, pharmaceutical product sales, and wellness-related facilities, supported by its investment arm and financial assets portfolio. The company’s latest major changes include recent equity issuances totaling millions of new ordinary shares in 2026 to broaden the share base and liquidity, governance and organizational updates tied to its restructuring and ongoing portfolio optimization, and expansion of its health management and medical services network through partnerships and potential new clinic formats; it also announces ongoing enhancements to its product lines and service offerings, and has pursued strategic partnerships to strengthen its integrated healthcare platform. Primary product and service offerings comprise medical centre operations for tumor-related diagnosis and treatment; optical products and eye-care services retail; manufacturing and sale of pharmaceutical and health-related products; medical laboratory testing services; health check and obstetric/gynaecological services; operation of sports and healthcare clubhouses; and asset management activities including investments in financial assets and distressed assets as well as loan financing. The company’s target markets include individual patients seeking diagnostic and treatment services, optical and eye-care consumers, corporate and institutional clients seeking health management solutions, and financial partners engaging in asset-based investment strategies; geographic reach concentrates in Hong Kong and Mainland China with ancillary activity in international markets via its asset management operations. Subsidiaries and investment vehicles operate under SoftMedx’s umbrella, with parent-subsidiary relationships designed to synergize clinical services, consumer health products, and financial asset management to deliver an integrated healthcare and wellness platform.